JS 001

Drug Profile

JS 001

Alternative Names: anti-PD-I mAb-Shanghai Junshi; Anti-PD1 monoclonal antibody - Shanghai Junshi; JS001; TAB-001

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Junshi Biosciences
  • Developer Fudan University; Peking University; Shanghai Junshi Biosciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Bladder cancer; Non-small cell lung cancer
  • Phase I/II Gastric cancer; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Phase I Breast cancer; Cancer; Neuroendocrine tumours; Prolactinoma; Renal cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 10 Jul 2018 CSPC Pharmaceutical and Shanghai Junshi Biosciences agree to develop and market anti-PD-1 monoclonal antibody in Hong Kong, Taiwan and Macau for Breast cancer
  • 10 Jul 2018 Shanghai Junshi Bioscience plans a phase III trial for Nasophapyngeal cancer in China, Singapore and Taiwan (NCT03581786)
  • 01 Jun 2018 Adverse events and efficacy data from a phase-II trial in advanced or metastatic Melanoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top